Citations

Showing 10 of 108135 citations.

Fully automated quantification of cardiac chamber and function assessment in 2-D Echocardiography: clinical feasibility of deep learning-based algorithms
Kim, Sekeun , Jeon, Jaeik, Park, Hyung‐Bok , Jeon, Jaeik , Arsanjani, Reza , Heo, Ran , Lee, Sang‐Eun , Moon, Inki , Yoo, Sun Kook , Chang, Hyuk‐Jae

Mayo Clinic

No container title available | September 30, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-945163/v1 Get It

Abstract Objectives: We aimed to compare the segmentation performance of the current prominent deep learning (DL) algorithms with ground-truth segmentations and to validate the reproducibility of the manually created 2D echocardiographic four cardiac chamber ground-truth annotation.Background: Recently emerged DL based fully-automated chamber segmentation and function assessment methods have shown great potential for future application in aiding image acquisition, quantification, and suggestion for diagnosis. However, the performance of current DL algorithms have not previously been compared with each other. In addition, the reproducibility of ground-truth annotations which are the basis of these algorithms have not yet been fully validated.Methods: We retrospectively enrolled 500 consecutive patients who underwent transthoracic echocardiogram (TTE) from December 2019 to December 2020. Simple U-net, Res-U-net, and Dense-U-net algorithms were compared for the segmentation performances and clinical indices such as left atrial volume (LAV), left ventricular end diastolic volume (LVEDV), LV end systolic volume (LVESV), LV mass, and ejection fraction (EF) were evaluated. The inter- and intra- observer variability analysis was performed by two expert sonographers for a randomly selected echocardiographic view in 100 patients (apical 2-chamber, apical 4-chamber, and parasternal short axis views).Results: The overall performance of all DL methods was excellent (average Dice similarity coefficient (DSC) 0.91 to 0.95 and average Intersection over union (IOU) 0.83 to 0.90), with the exception of LV wall area on PSAX view (average DSC of 0.83, IOU 0.72). In addition, there were no significant difference in clinical indices between ground truth and automated DL measurements. For inter- and intra observer variability analysis, the overall intra observer reproducibility was excellent: LAV (ICC = 0.995), LVEDV (ICC = 0.996), LVESV (ICC = 0.997), LV mass (ICC = 0.991) and EF (ICC = 0.984). The inter-observer reproducibility was slightly lower as compared to intraobserver agreement: LAV (ICC = 0.976), LVEDV (ICC = 0.982), LVESV (ICC =0.970), LV mass (ICC = 0.971), and EF (ICC = 0.899).Conclusions: The three current prominent DL-based fully automated methods are able to reliably perform four-chamber segmentation and quantification of clinical indices. Furthermore, we were able to validate the four cardiac chamber ground-truth annotation and demonstrate an overall excellent reproducibility, but still with some degree of inter-observer variability.
Radial strain imaging-guided lead placement for improving response to cardiac resynchronization therapy in patients with ischaemic cardiomyopathy: the Raise CRT trial
Glikson, Michael , Beinart, Roy , Golovchiner, Gregory , Sheshet, Alon Bar, Bolous, Munther, Rosso, Raphaël , Medina, Aharon , Haim, Moti , Friedman, Paul A. , Khalamaizer, Vladimir, Ben‐Zvi, Shlomit, Klempfner, Robert , Vaturi, Ori, Oh, Jae K. , Ito, Saki , Goldenberg, Ilan , Beinart, Roy , Haim, Moti , Glikson, Michael , Swissa, Moshe , Goldenberg, Ilan

Mayo Clinic

EP Europace | September 30, 2021 | Volume: 24 | Issue: 5 | Pages: 835-844

10.1093/europace/euab253 | PMID 34734227 Get It

Abstract Aims To evaluate the benefit of speckle tracking radial strain imaging (STRSI)-guided left ventricular (LV) lead (LVL) positioning in cardiac resynchronization therapy (CRT) in patients (pts) with ischaemic cardiomyopathy with CRT indication. Methods and results We conducted a prospective randomized controlled trial. Patients were enrolled in nine centres with 2:1 randomization into two groups (guided vs. control). Patients underwent STRSI to identify the optimal LV position from six LV segments at midventricular level. Implantation via STRSI was attempted for recommended segment in the guided group only. Follow-up included echocardiography (6 months) and clinical evaluation (6 and 12 months). The primary endpoint was comparison % reduction in LV end-systolic volume at 6 months with baseline. Secondary endpoints included hospitalizations for heart failure and death, and improvement in additional echocardiographic measurements and quality of life score. A total of 172 patients (115 guided vs. 57 control) were enrolled. In the guided group, 60% of the implanted LV leads were adjudicated to be successfully located at the recommended segment, whereas in the control group 44% reached the best STRSI determined segment. There was no difference between the groups in any of the primary or secondary endpoints at 6 and 12 months. Conclusion Our findings suggest that echo-guided implantation of an LV lead using STRSI does not improve the clinical or echocardiographic response compared with conventional implantation.
Is metformin use associated with a reduced risk of oesophageal cancer? A systematic review and meta-analysis
Chen, Yue , Cheng, Xingyu , Sun, Chenyu , Kim, Na Hyun , Kailas, Sujatha, Qureshi, Faisal, Karadsheh, Zeid, Wu, Yile , Hu, Lei , Zhou, Zhen , Bhan, Chandur , Kim, Keun Young , Manem, Raveena, Cheng, Ce , Zhou, Qin , Sun, Chenyu

Mayo Clinic

Postgraduate Medical Journal | September 30, 2021 | Volume: 98 | Issue: 1165 | Pages: 866-870

10.1136/postgradmedj-2021-140432 | PMID 37063031 Get It

AbstractObjectivesStudies on the association between metformin use and the risk of oesophageal cancer (OC) have generated controversial findings. This updated meta-analysis was conducted to reassess the effects of metformin on OC.MethodsA comprehensive search strategy was conducted to select relevant studies from origination to February 2021. Heterogeneity was evaluated through the Q test and I2 statistics. HRs and 95% CIs were pooled through either random-effect or fixed-effect models. Meta-regression, subgroup analyses, sensitivity analysis and publication bias diagnosis were also performed.ResultsSeven studies with 5 426 343 subjects were included. Metformin use was associated with reduced risk of OC (HR=0.69, 95% CI 0.54 to 0.87, p<0.001). Sensitivity analysis suggested that the results were relatively stable.ConclusionMetformin is associated with a reduced risk of OC. More well-designed studies are still needed to further elaborate on these associations.PROSPERO registration numberCRD42021237127.
Risk of hypertension in erenumab‐treated patients with migraine: Analyses of clinical trial and postmarketing data
Dodick, David W. , Tepper, Stewart J. , Pannacciulli, Nicola, Navetta, Marco S., Loop, Brett, Zhang, Feng , Khodavirdi, Ani C., Mann, Allison, Abdrabboh, Ahmad, Kalim, Jawed, Dodick, David W , Ailani, Jessica

Mayo Clinic

Headache: The Journal of Head and Face Pain | September 30, 2021 | Volume: 61 | Issue: 9 | Pages: 1411-1420

10.1111/head.14208 | PMID 34591982 Get It

Abstract Objective To assess the risk of hypertension in patients with migraine who received erenumab in clinical trials and in the postmarketing setting. Background Erenumab is a monoclonal antibody for migraine prevention that targets the calcitonin gene‐related peptide (CGRP) receptor. Hypertension is a theoretical risk for inhibitors of the CGRP pathway. Although no evidence of an association between erenumab treatment and hypertension was observed during the clinical development program, adverse events (AEs) of hypertension have been identified in the postmarketing setting. Methods Safety data from four phase 2 and phase 3 clinical trials were used to perform a pooled analysis of hypertension AEs in patients with migraine receiving erenumab. Postmarketing AEs of hypertension were identified from the Amgen Global Safety database from May 17, 2018, through January 31, 2020. Results In the pooled analysis of clinical trials, hypertension AEs (placebo, 9/1043 [0.9%]; erenumab 70 mg, 7/893 [0.8%]; erenumab 140 mg, 1/507 [0.2%]) and percentage of patients initiating medication to treat hypertension (12/1043 [1.2%], 7/893 [0.8%], 1/507 [0.2%], respectively) were similar across treatment groups. A total of 362 AEs of hypertension were identified from the postmarketing setting, 26.2% (95/362) of which were serious, >245,000 patient‐years of exposure. The exposure‐adjusted incidence of hypertension was 0.144 per 100 patient‐years. Conclusions Clinical trials did not demonstrate an increased risk of hypertension with erenumab compared with placebo, and AE rates of hypertension reported with erenumab in the postmarketing setting were generally low. Additional data are needed to fully characterize the extent to which hypertension is a risk associated with erenumab.
Oncogenic KRAS drives radioresistance through upregulation of NRF2-53BP1-mediated non-homologous end-joining repair
Yang, Linlin , Shen, Changxian , Estrada‐Bernal, Adriana , Sebastian, Nikhil , Chen, Wei , Williams, Terence M , Chen, Wei , Robb, Ryan N. , Chatterjee, Moumita , Webb, Amy , Mo, Xiaokui Molly , Chen, Wei , Krishnan, Sunil , Williams, Terence M.

Mayo Clinic

Nucleic Acids Research | September 30, 2021 | Volume: 49 | Issue: 19 | Pages: 11067-11082

10.1093/nar/gkab871 | PMID 34606602 Get It

Abstract KRAS-activating mutations are oncogenic drivers and are correlated with radioresistance of multiple cancers, including colorectal cancer, but the underlying precise molecular mechanisms remain elusive. Herein we model the radiosensitivity of isogenic HCT116 and SW48 colorectal cancer cell lines bearing wild-type or various mutant KRAS isoforms. We demonstrate that KRAS mutations indeed lead to radioresistance accompanied by reduced radiotherapy-induced mitotic catastrophe and an accelerated release from G2/M arrest. Moreover, KRAS mutations result in increased DNA damage response and upregulation of 53BP1 with associated increased non-homologous end-joining (NHEJ) repair. Remarkably, KRAS mutations lead to activation of NRF2 antioxidant signaling to increase 53BP1 gene transcription. Furthermore, genetic silencing or pharmacological inhibition of KRAS, NRF2 or 53BP1 attenuates KRAS mutation-induced radioresistance, especially in G1 phase cells. These findings reveal an important role for a KRAS-induced NRF2-53BP1 axis in the DNA repair and survival of KRAS-mutant tumor cells after radiotherapy, and indicate that targeting NRF2, 53BP1 or NHEJ may represent novel strategies to selectively abrogate KRAS mutation-mediated radioresistance.
Defining Antibiotic Inertia: Application of a Focused Clinical Scenario Survey to Illuminate A New Target for Antimicrobial Stewardship During Transitions of Care
Kooda, Kirstin , Dierkhising, Ross , Kooda, Kirstin , Bellolio, Fernanda , Tande, Aaron J.

Mayo Clinic

Clinical Infectious Diseases | September 30, 2021 | Volume: 74 | Issue: 11 | Pages: 2050-2052

10.1093/cid/ciab872 | PMID 34596206 Get It

Abstract In clinical scenario surveys, inpatient providers were more likely to report continuing inappropriate (odds ratio, 2.02 [95% confidence interval, 1.35–3.03]; P<.001) or broad-spectrum (1.8 [1.27–2.56]; P=.001) antibiotic therapy when initiated by emergency department providers, than to change to appropriate or narrow-spectrum therapy, respectively. Antibiotic inertia could represent a significant antibiotic stewardship target.
Proposed research criteria for prodromal behavioural variant frontotemporal dementia
Barker, Megan S. , Gottesman, Reena , Manoochehri, Masood , Chapman, Silvia , Brushaber, Danielle , Devick, Katrina L. , Domoto‐Reilly, Kimiko , Fields, Julie A. , Forsberg, Leah K. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Heuer, Hilary W. , Kornak, John , Mackenzie, Ian R. , Masdeu, Joseph C. , Mendez, Mario F, Pascual, Belén , Staffaroni, Adam M. , Tartaglia, Maria Carmela , Boxer, Adam L. , Rosen, Howard J. , Rankin, Katherine P. , Cosentino, Stephanie , Rascovsky, Katya, Huey, Edward D. , Kaufer, Daniel , Onyike, Chiadi U. , Ritter, Aaron, Weıntraub, Sandra , Devick, Katrina L , Masdeu, Joseph C , Pascual, Belen , Boeve, Brad , Tartaglia, Maria Carmela , Domoto-Reilly, Kimiko , Appleby, Brian S. , Dickerson, Bradford Clark , Galasko, Douglas , Goldman, Jill , Grossman, Murray , Hsiung, Ging‐Yuek Robin , Knopman, David S. , Litvan, Irene , Mendez, Mario F, Boeve, Bradley F. , Foroud, Tatiana , Kremers, Walter K. , Léger, Gabriel C. , Roberson, Erik D.

Mayo Clinic

Brain | September 30, 2021 | Volume: 145 | Issue: 3 | Pages: 1079-1097

10.1093/brain/awab365 | PMID 35349636 Get It

Abstract At present, no research criteria exist for the diagnosis of prodromal behavioural variant frontotemporal dementia (bvFTD), though early detection is of high research importance. Thus, we sought to develop and validate a proposed set of research criteria for prodromal bvFTD, termed ‘mild behavioural and/or cognitive impairment in bvFTD’ (MBCI-FTD). Participants included 72 participants deemed to have prodromal bvFTD; this comprised 55 carriers of a pathogenic mutation known to cause frontotemporal lobar degeneration, and 17 individuals with autopsy-confirmed frontotemporal lobar degeneration. All had mild behavioural and/or cognitive changes, as judged by an evaluating clinician. Based on extensive clinical workup, the prodromal bvFTD group was divided into a Development Group (n = 22) and a Validation Group (n = 50). The Development Group was selected to be the subset of the prodromal bvFTD group for whom we had the strongest longitudinal evidence of conversion to bvFTD, and was used to develop the MBCI-FTD criteria. The Validation Group was the remainder of the prodromal bvFTD group and was used as a separate sample on which to validate the criteria. Familial non-carriers were included as healthy controls (n = 165). The frequencies of behavioural and neuropsychiatric features, neuropsychological deficits, and social cognitive dysfunction in the prodromal bvFTD Development Group and healthy controls were assessed. Based on sensitivity and specificity analyses, seven core features were identified: apathy without moderate-severe dysphoria, behavioural disinhibition, irritability/agitation, reduced empathy/sympathy, repetitive behaviours (simple and/or complex), joviality/gregariousness, and appetite changes/hyperorality. Supportive features include a neuropsychological profile of impaired executive function or naming with intact orientation and visuospatial skills, reduced insight for cognitive or behavioural changes, and poor social cognition. Three core features or two core features plus one supportive feature are required for the diagnosis of possible MBCI-FTD; probable MBCI-FTD requires imaging or biomarker evidence, or a pathogenic genetic mutation. The proposed MBCI-FTD criteria correctly classified 95% of the prodromal bvFTD Development Group, and 74% of the prodromal bvFTD Validation Group, with a false positive rate of <10% in healthy controls. Finally, the MBCI-FTD criteria were tested on a cohort of individuals with prodromal Alzheimer’s disease, and the false positive rate of diagnosis was 11–16%. Future research will need to refine the sensitivity and specificity of these criteria, and incorporate emerging biomarker evidence.
Assessment of 2-Year Storage Conditions on Protein, RNA, and DNA in Unstained Human Tissue Sections, Including a Novel Multiplex Digital Gene Expression Profiling Method with Implications for Biobanking
Ramsower, Colleen , Wisner, Lee, Zellner, Katie R. , Glinsmann‐Gibson, Betty, Larsen, Brandon T. , McGrath, Michael S. , Maguire, Alanna , Rimsza, Lisa M. , Maguire, Alanna , Zellner, Katie, Larsen, Brandon, Rimsza, Lisa M , Ramsower, Colleen A , Maguire, Alanna

Mayo Clinic

Biopreservation and Biobanking | September 30, 2021 | Volume: 20 | Issue: 6 | Pages: 473-484

10.1089/bio.2021.0023 | PMID 34591685 Get It

Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT–Identified Oligometastatic Castration-Resistant Prostate Cancer
Zhang, Henan , Orme, Jacob J. , Abraha, Feven , Stish, Bradley J. , Lowe, Val J. , Tryggestad, E., Bold, Michael S., Pagliaro, Lance C. , Choo, C. Richard, Brinkmann, Debra H. , Iott, Matthew J., Quevedo, J. Fernando , Harmsen, William S. , Costello, Brian A. , Johnson, Geoffrey B. , Nathan, Mark A., Olivier, Kenneth R. , Pisansky, Thomas M. , Kwon, Eugene D., Tryggestad, Erik J, Brinkmann, Debra H , Davis, Brian J. , Costello, Brian A , Johnson, Geoffrey B , Dong, Haidong , Park, Sean S , Lucien, Fabrice , Dong, Haidong , Park, Sean S.

Mayo Clinic

Clinical Cancer Research | September 30, 2021 | Volume: 27 | Issue: 23 | Pages: 6376-6383

10.1158/1078-0432.ccr-21-2510 | PMID 34593526 Get It

Abstract Purpose: Outcomes for resistant metastatic castration-resistant prostate cancer (CRPC) are poor. Stereotactic ablative radiotherapy (SABR) induces antitumor immunity in clinical and preclinical studies, but immunologic biomarkers are lacking. Patients and Methods: Eighty-nine patients with oligometastatic CRPC were identified by 11C-Choline-PET (Choline-PET) from August 2016 to December 2019 and treated with SABR. Prespecified coprimary endpoints were 2-year overall survival (OS) and PSA progression. Secondary endpoints included 2-year SABR-treated local failure and 6-month adverse events. Correlative studies included peripheral blood T-cell subpopulations before and after SABR. Results: 128 lesions in 89 patients were included in this analysis. Median OS was 29.3 months, and 1- and 2-year OS were 96% and 80%, respectively. PSA PFS was 40% at 1 year and 21% at 2 years. Local PFS was 84.4% and 75.3% at 1 and 2 years, respectively, and no grade ≥3 AEs were observed. Baseline high levels of tumor-reactive T cells (TTR; CD8+CD11ahigh) predicted superior local, PSA, and distant PFS. Baseline high levels of effector memory T cells (TEM; CCR7−CD45RA−) were associated with improved PSA PFS. An increase in TTR at day 14 from baseline was associated with superior OS. Conclusions: This is the first comprehensive effector T-cell immunophenotype analysis in a phase II trial before and after SABR in CRPC. Results are favorable and support the incorporation of immune-based markers in the design of future randomized trials in patients with oligometastatic CRPC treated with SABR.